The UVTech Transfer Office has signed a licensing agreement with Chinese company Hockley Pharmaceuticals, its US subsidiary, Licensing Handle Holdings.
Campus, all biochemistry departments of the Department of Chemistry and Tomikaz Saski’s Department of AV, developed by scientists Henry Lai and Narendra Singh, use a substance known as artemisinin, which is found in vertical wood plants. Is and is used all over Asia. Time to treat malaria.
“We are very excited about the discovery of UW and the opportunity to develop artemisinin-based cancer drugs,” said Holley’s chief scientist. “The technology is exciting, but it’s in the early stages. More research and clinical trials are needed.”
Officials say the company, based in Chiang Qing, China, has been in the artemisinin business for more than 30 years, and is a global leader in plants, drainage and manufacturers of anti-malarial drugs based on carmine, grains and artemisinin.
Lee said he wondered if the procedure could also work with cancer.
Perhaps the most promising of the licensed methods involves the use of transfers, on which researchers are bound to the level of contamination with artemisinin. Transferean is a protein ranging from iron found in the blood, and is transmitted to cells through transferase receptors at the cell level.
“We call it the Trojan Horse because it recognizes the transfer of a cancer cell as a natural, harmful protein and picks up the tagged compound without knowing that the bomb – Artesian – is hidden.”
Once inside the cancer cell, iron is released and reacts with artemisinin. Its compound is highly toxic and, therefore, highly selective due to its strong need for iron. Around it, healthy cells are essentially hopeless.